Navigation Links
Ten years later, Dolly is still making headlines

The lead researcher for the team who - 10 years ago - created the cloned sheep "Dolly," will kick off the 2006 American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in Boston, June 18-21. At the meeting, nearly two-thousand of the world's leading scientists will discuss a variety of critical issues affecting pharmaceutical biotechnology including Biogenerics, a field that is being hailed as the next revolution in healthcare.

"At AAPS, we are committed to tackling the latest issues ?even the toughest issues ?and exposing our members to disparate points of view so they ?as the most highly trained scientists in the world ?can draw their own conclusions," said John Lisack, AAPS executive director. "With topics like cloning and biogenerics headlining this year's event, there is no more exciting and challenging time to be in the field of pharmaceutical sciences than now."

The following topics will headline this year's meeting:

Creator of "Dolly" and world-renowned scientists share insight

Making his first U.S. appearance since his book, About Dolly, hit shelves earlier this month, Dr. Ian Wilmut, the lead researcher of a team of scientists who were first to successfully clone an animal, Dolly the sheep, ten years ago, will speak about his plans to clone embryos to alter disease genes in humans. Wilmut will be joined by two other leaders in biotechnology research, Dr. Kevin Eggan of the Harvard Stem Cell Institute, where plans were just announced to create the world's first cloned human embryonic stem cells, and Dr. Burt Adelman of Biogen Idec, the company that produces the recently re-approved multiple sclerosis drug, Tysabri. The Plenary Session is Monday, June 19 from 8:30 a.m. to 11:30 a.m. at the Hynes Convention Center.

Biogenerics ?The next revolution in health care?

Generic biopharmaceutical drugs, or biogenerics, are widely available in Europe and Australia, but the first biogeneric was just approved last month in the United States by the Food and Drug Administration (FDA). This approval has opened a pandora's box of issues. Biopharmaceutical medications are some of the most expensive medicines on the market. Approving generic formulas, therefore, has the potential to put once inaccessible drugs within the reach of millions more people, but at what cost? At the Boston meeting, there will be an Open Forum on Sunday, June 18 from 8 a.m. to 5:15 p.m. in the Hynes Convention Center to discuss the various regulatory, scientific and ethical issues surrounding generic biopharmaceuticals, as well as:

  • Why is the FDA slow to approve biogenerics?
  • What are the risks of a biogeneric drug, like a human growth hormone, being used for the off-label purpose of anti-aging?
  • With $20B of biotechnology-derived product losing patent protection over the next few years, how will the FDA handle this influx of legal and regulatory challenges?

National Biotechnology Conference

The AAPS National Biotechnology Conference is an annual event incorporating all aspects of pharmaceutical biotechnology and providing an open forum for discussion of industry topics. The conference will take place June 18?1 at the John B. Hynes Convention Center, Boston, Mass.


'"/>

Source:American Association of Pharmaceutical Scientists


Related biology news :

1. Artifical cornea lets woman blind 20 years see
2. Retrovirus struck ancestors of chimpanzees and gorillas millions of years ago, but did not affect ancestral humans
3. Hunger in America rises by 43 percent over last five years
4. Picky female frogs drive evolution of new species in less than 8,000 years
5. Bone marrow stem cells may heal hearts even years after heart attacks
6. Carbon cycle was already disrupted millions of years ago
7. Ancient ants arose 140-168 million years ago
8. Bt cotton in China fails to reap profit after seven years
9. UCLA scientists strengthen case for life more than 3.8 billion years ago
10. Allergy battle could be won in five years, says scientist
11. Scientists describe new African monkey genus ?first in 83 years
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... 2016 , ... Clinovo , the cloud-based eClinical software ... Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) Partner Program ... San Mateo, California on February 10th and 11th. Watch 2-min video . ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016 Novan, Inc. today ... Chairman of the Board of Directors of Novan. In addition, ... North Carolina . --> ... Company also announced that it received a total of $32.8 million ... 2015 from its private investor network originating throughout the Research Triangle ...
Breaking Biology Technology: